RUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company pioneering new technologies for diabetes management, has announced ethical approval for a long-term clinical study of its Continuous Blood Glucose Monitor (CBGM). The study, approved by the St. Vincent's Hospital Melbourne Human Research Ethics Committee, will involve up to 30 participants with type 1 and type 2 diabetes who require glucose monitoring and intensive insulin therapy. This single arm, multi-center study aims to evaluate the performance and safety of the CBGM over an initial one-year period, with potential extensions up to three years. The device is notable for its implantable nature, eliminating the need for on-body wearables, and directly measures blood glucose, potentially offering more accurate real-time glucose values. The first patient implants are expected by July, under the leadership of Principal Investigator Professor David O'Neal.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.